Second round results from the Manchester ‘Lung Health Check’ community-based targeted lung cancer screening pilot

Phil A Crosbie, Haval Balata, Matthew Evison, Melanie Atack, Val Bayliss-Brideaux, Denis Colligan, Rebecca Duerten, Josephine Eaglesfield, Timothy Edwards, Peter Elton, Julie Foster, Melanie Greaves, Graham Hayler, Coral Higgins, John Howells, Klaus Iriion, Devinda Karunaratne, Jodie Kelly, Zoe King, Judith Lyons, Sarah Manson, Stuart Mellor, Donna Miller, Amanda Myerscough, Tom Newton, Michelle O’Leary, Rachel Pearson, Julie Pickford, Richard Sawyer, Nick J Sceaton, Anna Sharman, Maggi Simmons, Elaine Smith, Ben Taylor, Sarah Taylor, Anna Walsham, Anthony Threlfall, Phil V Barber, Janet Tonge, Richard Booton

ABSTRACT

We report results from the second annual screening round (T1) of Manchester’s ‘Lung Health Check’ pilot of community-based lung cancer screening in deprived areas (undertaken June to August 2017). Screening adherence was 90% (n=1194/1323); 92% of CT scans were classified negative, 6% indeterminate and 2.5% positive; there were no interval cancers. Lung cancer incidence was 1.6% (n=19), 79% stage I, treatments included surgery (42%, n=9), stereotactic ablative radiotherapy (26%, n=5) and radical radiotherapy (5%, n=1). False-positive rate was 34.5% (n=10/29), representing 0.8% of T1 participants (n=10/1194). Targeted community-based lung cancer screening promotes high screening adherence and detects high rates of early stage lung cancer.

INTRODUCTION

The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer-specific mortality with annual low-dose CT (LDCT) screening of high-risk ever smokers compared with chest X-ray. A key requirement for screening implementation is to ensure services are accessible to those at greatest risk. In Manchester, we developed a community-based ‘Lung Health Check’ (LHC) approach to target high-risk smokers in deprived areas. LHCs were nurse-led and included calculation of lung cancer risk using the PLCO$_{2012}$ risk model. Those at higher risk were invited to a LHC; this consisted of 6-year lung cancer risk calculation (PLCO$_{2012}$), symptom assessment, smoking cessation advice and spirometry. Individuals at higher risk (defined as ≥1.51% over 6 years) were offered annual LDCT screening. All LDCT scans (Optima 660; GE Healthcare) were reported by National Health Service (NHS) consultant radiologists with an interest in thoracic radiology and classified as either negative, indeterminate or positive. Pulmonary nodules were managed in accordance with British Thoracic Society (BTS) guidelines adapted for an annual screening programme. Indeterminate scans required surveillance imaging at 3 months and positive scans had findings concerning for lung cancer requiring immediate assessment in the rapid access lung cancer clinic based in a specialist centre. A false positive was any screened individual referred to the lung cancer clinic who was not diagnosed with lung cancer. An interval cancer was defined as any lung cancer diagnosed outside of screening before the second-round scan (T1). Volume doubling times (VDTs) were calculated in accordance with BTS guidelines. VDT was estimated in those without a nodule at baseline (T0) by assuming the nodule appeared the day after the CT scan was performed and measured 1 mm. Lung cancers were managed in accordance with national guidelines. The seventh edition of TNM lung cancer staging manual was used. In this paper, the first screening round is referred to as T0 and the second screening round 12 months later as T1. Individuals with an indeterminate scan at T1 had a further LDCT scan 3 months later, which we refer to as the ‘3-month surveillance’ scan.

METHODS

A description of the screening pilot has previously been published. In brief, ever smokers aged 55–74 at participating general practices (n=14) were invited to a LHC; this consisted of 6-year lung cancer risk calculation (PLCO$_{2012}$), symptom assessment, smoking cessation advice and spirometry. Individuals at higher risk (defined as ≥1.51% over 6 years) were offered annual LDCT screening. All LDCT scans (Optima 660; GE Healthcare) were reported by National Health Service (NHS) consultant radiologists with an interest in thoracic radiology and classified as either negative, indeterminate or positive. Pulmonary nodules were managed in accordance with British Thoracic Society (BTS) guidelines adapted for an annual screening programme. Indeterminate scans required surveillance imaging at 3 months and positive scans had findings concerning for lung cancer requiring immediate assessment in the rapid access lung cancer clinic based in a specialist centre. A false positive was any screened individual referred to the lung cancer clinic who was not diagnosed with lung cancer. An interval cancer was defined as any lung cancer diagnosed outside of screening before the second-round scan (T1). Volume doubling times (VDTs) were calculated in accordance with BTS guidelines. VDT was estimated in those without a nodule at baseline (T0) by assuming the nodule appeared the day after the CT scan was performed and measured 1 mm. Lung cancers were managed in accordance with national guidelines. The seventh edition of TNM lung cancer staging manual was used. In this paper, the first screening round is referred to as T0 and the second screening round 12 months later as T1. Individuals with an indeterminate scan at T1 had a further LDCT scan 3 months later, which we refer to as the ‘3-month surveillance’ scan.

RESULTS

Ninety per cent of those eligible had a T1 scan (June to August 2017) (n=1194/1323). Non-attendees were significantly more likely to be current smokers (63.6% vs 50.6%, p=0.005), but there was no difference according to deprivation.

For numbered affiliations see end of article.

Correspondence to
Dr Phil A Crosbie, Manchester Thoracic Oncology Centre, North West Lung Centre, Manchester University NHS Foundation Trust, Wythenshawe, M23 9LT, UK; philip.crosbie@manchester.ac.uk

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Table 1  Comparison of attendees and non-attendees of the second (T1) screening round

| Variable                              | T1 Screening round | P values |
|---------------------------------------|--------------------|----------|
|                                       | Attendees          | Non-attendees | |
| No of attendees (%)                   | 1194               | 129      | –        |
| Mean age (years±SD)                   | 64.7 (5.4)         | 64.2 (5.6) | 0.34     |
| Sex M/F (%)                           | 587/607 (50.8)     | 65/6/49.6 | 0.79     |
| Median IMD rank (IQR)                 | 2848 (3615)        | 2908 (4195) | 0.79     |
| BMI (±SD)                             | 28.5 (5.4)         | 28.3 (5.7) | 0.73     |
| Lung cancer risk (PLCO, saric±SD)     | 4.8 (3.8)          | 5.4 (4.7) | 0.13     |
| Education (%)                         |                    |          |          |
| Less than ‘O’ level                   | 822 (68.8)         | 93 (72.1) | 0.58     |
| ‘O’ level                             | 213 (17.8)         | 24 (18.6) |          |
| ‘A’ level                             | 44 (3.7)           | 3 (2.3)   |          |
| University/college                    | 77 (6.4)           | 5 (3.9)   |          |
| University degree                     | 26 (2.2)           | 4 (3.1)   |          |
| Postgraduate/professional             | 12 (1.0)           | 0         |          |
| Smoking status (%)                    |                    |          |          |
| Current                               | 604 (50.6)         | 82 (63.6) | 0.005    |
| Former                                | 590 (49.4)         | 47 (36.4) |          |
| Smoking exposure (mean±SD)            |                    |          |          |
| Duration (years)                      | 43.4 (8.3)         | 45.4 (7.0) | 0.008    |
| Cigarettes/day                        | 24.1 (12.8)        | 23.9 (12.5) | 0.83    |
| Pack-years                            | 51.2 (25.9)        | 53.4 (28.6) | 0.37    |
| Spirometry (mean±SD)                  |                    |          |          |
| FEV₁                                 | 2.16 (0.7)         | 2.08 (0.7) | 0.26     |
| % predicted FEV₁                      | 84.9 (24.5)        | 81.0 (21.6) | 0.09     |
| FVC                                  | 3.17 (1.0)         | 3.10 (1.0) | 0.44     |
| % predicted FVC                       | 100.4 (24.6)       | 96.3 (23.7) | 0.07     |
| FEV₁/FVC ratio                        | 67.9 (10.7)        | 67.6 (12.3) | 0.75     |
| Airflow obstruction                   |                    |          |          |
| Yes (%)                               | 588 (49.6)         | 63 (53.1) | 0.45     |
| COPD/emphysema (%)                    | 386 (32.2)         | 37 (28.7) | 0.40     |
| FH lung cancer (%)                    | 326 (27.3)         | 32 (24.8) | 0.54     |
| MRC Dyspnoea Score (%)                |                    |          |          |
| 1                                    | 781 (65.4)         | 72 (55.8) | 0.13     |
| 2                                    | 261 (21.9)         | 32 (24.8) |          |
| 3                                    | 98 (8.2)           | 14 (10.9) |          |
| 4                                    | 53 (4.4)           | 11 (8.5)  |          |
| 5                                    | 1 (0.1)            | 0         |          |
| Performance status (%)                |                    |          |          |
| 0                                    | 655 (54.9)         | 60 (46.5) | 0.12     |
| 1                                    | 403 (33.8)         | 46 (35.7) |          |
| 2                                    | 116 (9.7)          | 19 (14.7) |          |
| 3                                    | 20 (1.7)           | 4 (3.1)   |          |
| 4                                    | 0                  | 0         |          |

BMI, Body Mass Index; FH, family history; IMD, Index of Multiple Deprivation; MRC, Medical Research Council.

(p=0.79) (table 1). The majority of T1 scans were ‘negative’ (92%, n=1099) (figure 1); 71 were ‘indeterminate’ of which 84.1% (n=58/71) were for nodule surveillance. The 3-month surveillance imaging rate was significantly lower than T0 (6% vs 13.7%; p=0.0001); six individuals were reclassified positive after 3-month scans. Overall, 30 scans were ‘positive’ (2.5%, n=30/1194)—one patient declined assessment. Of 29 individuals seen, 19 were diagnosed with lung cancer and 10 were not. The false-positive rate was 34.5% (n=10/29), which represents 0.8% of T1 participants (n=10/1,194). This false-positive rate was significantly lower (p=0.0001) than T0 (corresponding values 48.1% and 2.8%) and over both screening rounds it was 44.5% and 3.5%, respectively. There were no interval cancers between T0 and T1. The incidence of lung cancer in T1 was 1.6% (n=19/1,194), 79% were stage I (n=15), 10.5% stage III (n=2) and 10.5% stage IV (n=2) (table 2). Pathological subtypes included adenocarcinoma (32%, n=6), squamous cell (21%, n=4), small cell (16%, n=3) and non-small cell lung cancer not otherwise specified (10.5%, n=2). A clinical diagnosis was confirmed by the multidisciplinary team in four cases without pathological confirmation (21%). Cancer treatments included surgery (42%, n=9), stereotactic ablative radiotherapy (26%, n=5) and radical radiotherapy (n=1) (table 2). One individual had surgery for a benign lesion (granulomatous disease). There were no deaths within 90 days of surgery.

Thirteen individuals with a negative baseline scan (T0) were diagnosed with lung cancer in the second round; after...
retrospective review, five were visible at baseline as sub-5 mm nodules and all were stage I at diagnosis (table 2). The T0 false-negative rate was therefore 0.4% (n=5/1337), negative predictive value 99.6%, sensitivity 89.4% and specificity 97.1%. The benign surgical resection rate over both rounds was 2.5% (n=1/40). Tumour VDT was highest in those with a true negative baseline scan (average 49±26 days), followed by false-negative (99±50 days) and indeterminate scans (297±215 days; p=0.009) (table 2).

DISCUSSION
In this paper, we report results from the second round of the Manchester ‘Lung Health Check’ pilot, a targeted lung cancer screening service based in deprived areas of Manchester. Screening adherence was high (90%) despite most participants being from the lowest decile of deprivation in England, emphasising the benefit of accessible community-based services. The incidence of lung cancer was 1.6% (n=19), most cancers were stage I (79%) and 89% of individuals with screen detected cancer were offered curative-intent treatment. Over both screening rounds, 4.4% of the cohort were diagnosed with lung cancer, equivalent to one cancer detected for every 23 people screened. This is high when compared with other studies and more than 2.5 times that seen in NLST (T0: 1.0%, T1: 0.7%) and NELSON (T0: 0.9%, T1: 0.7%).\textsuperscript{17} Our benign surgical resection rate was low at 2.5%, 10-fold lower than NLST and NELSON.\textsuperscript{17} The pathological confirmation rate and surgical resection rate are lower than reported in other trials. The exact reason for this is unclear but may be a consequence of higher deprivation and increased comorbidity in our population.

When reviewed retrospectively, five cancers diagnosed in the second screening round were present on baseline CT, and all were stage I (79%) and 89% of individuals with screen detected cancer were offered curative-intent treatment. Over both screening rounds, 4.4% of the cohort were diagnosed with lung cancer, equivalent to one cancer detected for every 23 people screened. This is high when compared with other studies and more than 2.5 times that seen in NLST (T0: 1.0%, T1: 0.7%) and NELSON (T0: 0.9%, T1: 0.7%).\textsuperscript{17} Our benign surgical resection rate was low at 2.5%, 10-fold lower than NLST and NELSON.\textsuperscript{17} The pathological confirmation rate and surgical resection rate are lower than reported in other trials. The exact reason for this is unclear but may be a consequence of higher deprivation and increased comorbidity in our population.

When reviewed retrospectively, five cancers diagnosed in the second screening round were present on baseline CT, and all were sub-5 mm solid nodules and therefore appropriately classified as negative in accordance with BTS guidelines.\textsuperscript{4} In all five cases, the cancers were stage I when detected, although with VDTs ranging from 51 to 163 days, there may have been a stage shift if we had adopted biennial rather than annual screening. This was also true for cancers that developed in individuals with true negative baseline scans; the estimated mean VDT of 49 days in this cohort suggests a more aggressive phenotype.

\textsuperscript{702} Crosbie PA, et al. Thorax 2019;74:700–704. doi:10.1136/thoraxjnl-2018-212547
Table 2  Clinical details of screen detected lung cancers

| T0 outcome   | Stage       | VDT (days) | Final stage | Pathology (subtype)                     | Treatment          |
|--------------|-------------|------------|-------------|----------------------------------------|--------------------|
| Indeterminate| pT1a N0     | 369        | IA          | Adenocarcinoma (acinar)                | Surgery            |
| Indeterminate| pT1a N0     | 148        | IA          | Adenocarcinoma (acinar)                | Surgery            |
| Indeterminate| pT1a N0     | 89         | IA          | Squamous                               | Surgery            |
| Indeterminate| pT1a N0     | 687*       | IA          | Adenocarcinoma (acinar)                | Surgery            |
| Indeterminate| pT1a N0     | 206        | IA          | Squamous                               | Surgery            |
| Indeterminate| pT1a N0     | 285        | IA          | Adenocarcinoma (micropapillary 50%, papillary 10%, lepidic 40%) | Surgery            |
| Negative†    | pT1a N0     | 142        | IA          | Adenocarcinoma (solid 80%, acinar 20%) | Surgery            |
| Negative     | cT1a N0     | 29†        | IA          | Clinical                               | SABR               |
| Negative†    | cT1a N0     | 163        | IA          | Clinical                               | SABR               |
| Negative†    | cT1b N0     | 51         | IA          | NSCLC (NOS)                            | SABR               |
| Negative     | cT1a N0     | 71§        | IA          | Squamous                               | SABR               |
| Negative     | cT1b N0     | 65         | IA          | Clinical                               | No treatment¶†     |
| Negative†    | pT2a N0     | –          | IB          | Adenocarcinoma (solid 80%, lepidic 20%) | Surgery            |
| Negative†    | cT2a N0     | 72         | IB          | NSCLC (NOS)                            | SABR               |
| Negative     | cT1a N2     | 37†        | IIIA        | Squamous                               | Chemoradiotherapy   |
| Negative     | pT1a N2     | 86§        | IIIA        | Small cell                             | Surgery/chemotherapy |
| Negative     | cT4 N2 M1a  | 341        | IV          | Small cell                             | Chemoradiotherapy   |
| Negative     | cT3 N3 M1b  | 16†        | IV          | Small cell                             | Chemoradiotherapy   |

*Morphology of nodule changed with increasing density despite low VDT.
†False negative, §sequential treatment, ¶adjuvant chemotherapy.
+Estimated VDT.
§VDT calculated between T1 and T1+3-month surveillance scans.
¶Had chemoradiotherapy for oesophageal cancer.
NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy; VDT, volume doubling time.

It is noteworthy that the proportion of attendees classified as false positive was three times lower in the second round than the first; the 3-month surveillance imaging rate was also 30% lower. This may be a consequence of having the baseline CT as a comparator; a similar finding was reported by the ITALUNG study investigators and suggests that the risk of screen-related harm may be greatest in the first round.8 Over both screening rounds, the false-positive rate was higher than NELSON but lower than other studies.1 8–10 In terms of baseline (T0) screening performance, the service had a sensitivity of 89.4% and specificity 97.1%. This represents a slightly lower sensitivity (93.8%) than NLST but a much improved specificity (73.4%).1 11

In conclusion, we have demonstrated that a targeted community-based lung cancer screening programme, delivered within the NHS, can engage those most at risk and detect a high proportion of curable early stage cancers.

Author affiliations
1Manchester Thoracic Oncology Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
2Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
3Manchester Clinical Commissioning Group, Macmillan Cancer Improvement Partnership, Manchester, UK
4Manchester Health and Care Commissioning, Manchester, UK
5Greater Manchester, Lancashire, South Cumbria Strategic Clinical Network, Manchester, UK
6Manchester City Council, Manchester, UK
7Department of Radiology, Royal Preston Hospital, Preston, UK
8Department of Radiology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
9Department of Radiology, Royal Blackburn Hospital, Blackburn, UK
10The Black Health Agency, Manchester, UK
11Macmillan Cancer Support, Manchester, UK
12Department of Radiology, Papworth Hospital, Cambridge, UK
13Department of Radiology, Christie NHS Foundation Trust, Manchester, UK
14Department of Radiology, Salford Royal NHS Foundation Trust, Salford, UK
15Department of Radiology, Stockport NHS Foundation Trust, Stockport, UK

Acknowledgements The Macmillan Cancer Improvement Partnership facilitated the design and development of the pilot. The service was delivered by the lung cancer team at Wythenshawe Hospital, Manchester University NHS Foundation Trust, in partnership with Alliance Medical. LDCT reporting was performed by a consortium of NHS consultant radiologists with subspecialty interest in thoracic medicine. The pilot service was commissioned by South Manchester Clinical Commissioning Group on behalf of the three Manchester Clinical Commissioning Groups. Community engagement was delivered by multiple members of the team and was led by MCIP and the Manchester CCGs in conjunction with Manchester City Council, Macmillan Cancer Support and BHA for Equality. This work was supported by the NIHR Manchester Biomedical Research Centre.

Contributors Service concept: RB, PAC, PVB, AT, JT. Service development by members of the Macmillan Cancer Improvement Partnership: JT, ZK, GH, CH, PVB, MA, VB-B, JE, DM, JF, MS, AM, MO’L, RP, JP, LY, AT, PE, DC, ST, RB, PAC, ES, DK, BT, DC,
Brief communication

ST. Service operation and delivery by the Manchester University NHS Foundation Trust lung cancer team: HB, ME, JJ, TE, JK, SMar, AWal, RD, MG, RS, AS, ES, PVb, PAC, RB. Radiology reporting by the radiology consortium: RD, MG, JH, Ki, DK, SMel, TN, RS, NJ, AS, ES, BT, AWat, JW. Analysis of data and drafting of manuscript: PAC, HB, ME, JJ, RB and guarantors of overall content: PAC, RB. Review, revision and agreement of final manuscript: all authors.

Funding The pilot was supported by funding from Macmillan Cancer Support.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES
1 Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.
2 Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. Thorax 2019;74:405–9.
3 Tammemägi MC, Katsi HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728–36.
4 Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015;70 Suppl 2:i1–i54.
5 Baldwin DR, White B, Schmidt-Hansen M, et al. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ 2011;342:d2110.
6 Rami-Porrot R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4–9.
7 van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221–9.
8 Lopes Pegna A, Picciotto G, Falaschi F, et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol 2013;8:866–75.
9 Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009;180:445–53.
10 Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308–15.